UBS Initiates Coverage on Novo Nordisk (NVO) with a Neutral
More News related to NVO
- Matrix Lighthouse Rating Changes 11/28
- Photo Release -- Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of Insulin Analogues
- Study Finds Cost of Diabetes in the United States Exceeds $217 Billion
- Antyra Enters into Licensing Agreement for Anticancer Agents from Novo Nordisk A/S
- Novo Nordisk Launches Levemir(R) Satisfaction Guarantee Program
More News related to New Coverage
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
UBS initiates coverage on Novo Nordisk (NYSE: NVO) with a Neutral.
Novo Nordisk A/S is a Denmark-based healthcare company. The Company provides diabetes care and has diabetes product portfolio in the industry, including insulin delivery systems.
Related Categories
New CoverageStocks Mentioned
-1.80Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
